B cell receptor signaling pathway and its therapeutic implications in B-cell lymphoma

doi:10.3969/j.issn.1006-7795.2025.03.006

Abstract

Abstract: B-cell lymphomas account for 70%－80% of non-Hodgkin lymphomas（NHL） and exhibit significant heterogeneity in genetic profiles, phenotypic characteristics, and clinical manifestations, posing substantial challenges for clinical management. The B-cell receptor (BCR) is a transmembrane receptor on the surface of B cells that plays a central regulatory role in B-cell development, activation, and adaptive immune responses. As a core mechanism driving malignant transformation in various B-cell malignancies, aberrant activation of the BCR signaling pathway, plays a pivotal role in B lymphoma pathogenesis. Dysregulated BCR signaling not only promotes tumor cell proliferation, survival, and anti-apoptotic capacity but also accelerates malignant progression. Consequently, researchers are vigorously exploring therapeutic strategies targeting BCR and its downstream pathways, including inhibitors of Bruton's tyrosine kinase (BTK) and PI3K, as well as direct BCR-targeted approaches. The central role of BCR signaling in lymphoma pathogenesis and treatment underscores its potential as a critical focus for future therapeutic development, offering new directions and hope for improved clinical outcomes.

Key words: B-cell lymphoma, B cell receptor, signal pathway, small molecule inhibitors, immunotherapy

CLC Number:

R733.1

Wang Jingwen, Li Zhenjun, Lyu Liangcheng, Yao Xiaoyu, Ding Ning. B cell receptor signaling pathway and its therapeutic implications in B-cell lymphoma[J]. Journal of Capital Medical University, 2025, 46(3): 436-441.

References

［1］Meng X, Min Q, Wang J Y. B cell lymphoma［J］. Adv Exp Med Biol, 2020, 1254: 161－181.
［2］Young R M, Phelan J D, Wilson W H, et al. Pathogenic B-cell receptor signaling in lymphoid malignancies: new insights to improve treatment［J］. Immunol Rev, 2019, 291(1): 190－213.
［3］Tkachenko A, Kupcova K, Havranek O. B-cell receptor signaling and beyond: the role of Igα (CD79a)/Igβ (CD79b) in normal and malignant B cells［J］. Int J Mol Sci, 2023, 25(1): 10.
［4］Young R M, Wu T Y, Schmitz R, et al. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens［J］. Proc Natl Acad Sci U S A, 2015, 112(44): 13447－13454.
［5］Melchers F. Checkpoints that control B cell development［J］. J Clin Invest, 2015, 125(6): 2203－2210.
［6］Dong Y, Pi X, Bartels-Burgahn F, et al. Structural principles of B cell antigen receptor assembly［J］. Nature, 2022, 612(7938): 156－161.
［7］Pinto D, Montani E, Bolli M, et al. A functional BCR in human IgA and IgM plasma cells［J］. Blood, 2013, 121(20): 4110－4114.
［8］Shimizu T, Mundt C, Licence S, et al. VpreB1/VpreB2/lambda 5 triple-deficient mice show impaired B cell development but functional allelic exclusion of the IgH locus［J］. J Immunol, 2002, 168(12): 6286－6293.
［9］Tiegs S L, Russell D M, Nemazee D. Receptor editing in self-reactive bone marrow B cells［J］. J Exp Med, 1993, 177(4): 1009－1020.
［10］Blanc P, Moro-Sibilot L, Barthly L, et al. Mature IgM-expressing plasma cells sense antigen and develop competence for cytokine production upon antigenic challenge［J］. Nat Commun, 2016, 7(1): 13600.
［11］Wienands J, Larbolette O, Reth M.Evidence for a preformed transducer complex organized by the B cell antigen receptor［J］. Proc Natl Acad Sci U S A, 1996, 93(15): 7865－7870.
［12］Davis R E, Ngo V N, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma［J］. Nature, 2010, 463(7277): 88－92.
［13］Wang L D, Clark M R. B-cell antigen-receptor signalling in lymphocyte development［J］. Immunology, 2003, 110(4): 411－420.
［14］Monroe J G. ITAM-mediated tonic signalling through pre-BCR and BCR complexes［J］. Nat Rev Immunol, 2006, 6(4): 283－294.
［15］Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switchrecombination and switch translocations in activated B cell-like diffuse large B cell lymphoma［J］. J Exp Med, 2007, 204(3): 633－643.
［16］Horikawa K, Martin S W, Pogue S L, et al. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors［J］. J Exp Med, 2007, 204(4): 759－769.
［17］Dogan I, Bertocci B, Vilmont V, et al. Multiple layers of B cell memory with different effector functions［J］. Nat Immunol, 2009, 10(12): 1292－1299.
［18］Chen L F, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas［J］. Cancer Cell, 2013, 23(6): 826－838.
［19］Xu W D, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma［J］. Blood, 2021, 138(13): 1110－1119.
［20］Küppers R. Mechanisms of B-cell lymphoma pathogenesis［J］. Nat Rev Cancer, 2005, 5(4): 251－262.
［21］Refaeli Y, Young R M, Turner B C, et al. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas［J］. PLoS Biol, 2008, 6(6): e152.
［22］Wang M L, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma［J］. N Engl J Med, 2013, 369(6): 507－516.
［23］Swerdlow S H, Campo E, Pileri S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms［J］. Blood, 2016, 127(20): 2375－2390.
［24］Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma［J］. J Exp Med, 2003, 198(6): 851－862.
［25］Rosenwald A, Wright G, Chan W C, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma［J］. N Engl J Med, 2002, 346(25): 1937－1947.
［26］Havranek O, Xu J D, Köhrer S, et al. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma［J］. Blood, 2017, 130(8): 995－1006.
［27］Zhang J, Liu D, Shen R, et al.Abstract 2599: discovery and pharmacological characterization of the second generation of Btk inhibitors with improved target selectivity and enhanced in vivo efficacy［J］. Cancer Res, 2015, 75(15_Supplement): 2599.
［28］Carnero Contentti E, Correale J. Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis［J］. Expert Opin Emerg Drugs, 2020, 25(4): 377－381.
［29］Herman S E M, Farooqui M, Bezabhie R, et al. In vivo effects of ibrutinib on bcr signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients［J］. Blood, 2012, 120(21): 185.
［30］Fruman D A, Chiu H, Hopkins B D, et al. The PI3K pathway in human disease［J］. Cell, 2017, 170(4): 605－635.
［31］Lannutti B J, Meadows S A, Herman S E M, et al. CAL-101, a p110delta selectivephosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability［J］. Blood, 2011, 117(2): 591－594.
［32］Aydin E, Faehling S, Saleh M, et al. Phosphoinositide 3-kinase signaling in the tumor microenvironment: what do we need to consider when treating chronic lymphocytic leukemia with PI3K inhibitors?［J］. Front Immunol, 2020, 11: 595818.
［33］Serrat N, Guerrero-Hernández M, Matas-Céspedes A, et al. PI3Kδ inhibition reshapes follicular lymphoma－immune microenvironment cross talk and unleashes the activity of venetoclax［J］. Blood Adv, 2020, 4(17): 4217－4231.
［34］Pecoraro C, Faggion B, Balboni B, et al. GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer［J］. Drug Resist Updat, 2021, 58: 100779.
［35］Gacche R N, Assaraf Y G. Redundant angiogenic signaling and tumor drug resistance［J］. Drug Resist Updat, 2018, 36: 47－76.
［36］Kobayashi T, Nakamura S, Taniguchi T, et al. Purification and characterization of a cytosolic protein-tyrosine kinase from porcine spleen［J］. Eur J Biochem, 1990, 188(3): 535－540.
［37］Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs［J］. Drug Discov Today, 2010, 15(13/14): 517－530.
［38］Liu D L, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies［J］. J Hematol Oncol, 2017, 10(1): 145.
［39］Horwitz S M, Feldman T A, Ye J C, et al. Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma［J］. Blood, 2021, 138: 622.
［40］Liu X F, Zhou H, Hu Y, et al. Sovleplenib (HMPL－523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study［J］. Lancet Haematol, 2023, 10(6): e406-e418.
［41］Lenz G, Tilly H, Ziepert M, et al. Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials［J］. Leukemia, 2024, 38(12): 2709－2711.
［42］Tilly H, Morschhauser F, Sehn L H, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma［J］. N Engl J Med, 2022, 386(4): 351－363.
［43］Sehn L H, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data［J］. Blood Adv, 2022, 6(2): 533－543.
［44］Srivastava S, Riddell S R. Engineering CAR-T cells: design concepts［J］. Trends Immunol, 2015, 36(8): 494－502.
［45］Leung I, Templeton M L, Lo Y, et al. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function［J］. Blood Adv, 2023, 7(12): 2718－2730.
［46］Julamanee J, Terakura S, Umemura K, et al. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival［J］. Mol Ther, 2021, 29(9): 2677－2690.